📊 Market Analysis

The global burden of diabetes and endocrine disorders continues to rise at an alarming pace, making these conditions a major public health challenge and a significant driver of healthcare expenditure worldwide. The 2nd World Congress on Diabetes and Endocrinology – 2026 comes at a crucial time, providing a platform to address both the scientific and commercial dimensions of this growing crisis.

🌍 Global Burden and Prevalence

• According to the International Diabetes Federation (IDF), over 537 million adults were living with diabetes in 2021. This number is projected to reach 783 million by 2045.
• More than 1.5 billion people globally suffer from various endocrine and metabolic disorders, including thyroid dysfunction, obesity, PCOS, and adrenal diseases.
• Type 2 diabetes accounts for over 90% of all diabetes cases and is increasingly affecting younger populations due to rising obesity, sedentary lifestyles, and urbanization.

💵 Economic Impact

• The global economic cost of diabetes is estimated to exceed USD 1 trillion annually, including both direct medical costs and lost productivity.
• Endocrine-related cancers and hormonal imbalances significantly contribute to healthcare utilization and disability-adjusted life years (DALYs).

🚀 Market Growth & Opportunities

• The global diabetes care market was valued at over USD 65 billion in 2023 and is expected to grow to USD 100+ billion by 2030.
• The endocrinology drugs market is projected to surpass USD 50 billion by 2028.
• Regions including North America, Europe, the Middle East, and Asia-Pacific are seeing rapid growth in diabetes technology investment.
• Wearable health tech, digital therapeutics, and personalized medicine are transforming care delivery and patient engagement.

🧪 R&D and Innovation Trends

• Therapeutic innovations include GLP-1/GIP dual agonists, oral semaglutide, and stem cell-based therapies.
• Research in AI-assisted diagnostics, molecular hormone therapies, and gene editing is paving the way for precision endocrinology.

The 2nd World Congress on Diabetes and Endocrinology – 2026 serves as a strategic forum for stakeholders—including clinicians, researchers, startups, pharma leaders, investors, and policymakers—to analyze market trends, exchange insights, and explore new avenues for collaboration and growth in this high-impact therapeutic area.